LEXEO Therapeutics, Inc. announced new clinical data from its ongoing study of LX1001 for APOE4-associated Alzheimer’s disease will be presented at the 29th European Society of Gene and Cell Therapy Annual Meeting, which is being held live in Edinburgh, Scotland and virtually from October 11-14, 2022.
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for cardiovascular and central nervous system (CNS) diseases, today announced new clinical data from its ongoing study of LX1001 for APOE4-associated Alzheimer’s disease will be presented at the 29th European Society of Gene and Cell Therapy Annual Meeting (ESGCT), which is being held live in Edinburgh, Scotland and virtually from October 11-14, 2022.
In an oral presentation, LEXEO will present clinical data from the ongoing study of LX1001 for APOE4-associated Alzheimer’s disease. LX1001 is an AAV-based investigational gene therapy designed to deliver the apolipoprotein E2 (APOE2) gene into the CNS of APOE4 homozygous Alzheimer’s disease patients to halt or slow disease progression. This marks the first clinical data from a gene therapy program targeting APOE4-associated Alzheimer’s disease presented at a scientific meeting.
Details of the oral presentation are:
Title: Gene Therapy in APOE4 Homozygote Alzheimer’s Disease – interim data
Presenter: Michael Kaplitt, M.D., Ph.D., Weill Cornell Medicine
Date/Time: Wednesday, October 12th, session start - 9:00 AM ET (15:00 CEST)
Session Title: CNS and sensory disease I (Parallel 3a)
To view full event programming, please visit the ESGCT website.
About LEXEO Therapeutics
LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic institutions at Weill Cornell Medicine and the University of California, San Diego. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates in rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing, and commercialization. For more information, please visit www.lexeotx.com or LinkedIn.
Media Contact:
Evan Feeley
Evoke Canale for LEXEO
(619) 849-5392
evan.feeley@evokegroup.com
